TY - JOUR
T1 - The relation between dopamine D2 receptor blockade and the brain reward system
T2 - a longitudinal study of first-episode schizophrenia patients
AU - Wulff, Sanne
AU - Nielsen, Mette Ødegaard
AU - Rostrup, Egill
AU - Svarer, Claus
AU - Jensen, Lars Thorbjørn
AU - Pinborg, Lars
AU - Glenthøj, Birte Yding
PY - 2020/1
Y1 - 2020/1
N2 - BACKGROUND: Psychotic symptoms have been linked to salience abnormalities in the brain reward system, perhaps caused by a dysfunction of the dopamine neurotransmission in striatal regions. Blocking dopamine D2 receptors dampens psychotic symptoms and normalises reward disturbances, but a direct relationship between D2 receptor blockade, normalisation of reward processing and symptom improvement has not yet been demonstrated. The current study examined the association between blockade of D2 receptors in the caudate nucleus, alterations in reward processing and the psychopathology in a longitudinal study of antipsychotic-naïve first-episode schizophrenia patients.METHODS: Twenty-two antipsychotic-naïve first-episode schizophrenia patients (10 males, mean age 23.3) and 23 healthy controls (12 males, mean age 23.5) were examined with single-photon emission computed tomography using 123I-labelled iodobenzamide. Reward disturbances were measured with functional magnetic resonance imaging (fMRI) using a modified version of the monetary-incentive-delay task. Patients were assessed before and after 6 weeks of treatment with amisulpride.RESULTS: In line with previous results, patients had a lower fMRI response at baseline (0.2 ± 0.5 v. 0.7 ± 0.6; p = 0.008), but not at follow-up (0.5 ± 0.6 v. 0.6 ± 0.7), and a change in the fMRI signal correlated with improvement in Positive and Negative Syndrome Scale positive symptoms (ρ = -0.435, p = 0.049). In patients responding to treatment, a correlation between improvement in the fMRI signal and receptor occupancy was found (ρ = 0.588; p = 0.035).CONCLUSION: The results indicate that salience abnormalities play a role in the reward system in schizophrenia. In patients responding to a treatment-induced blockade of dopamine D2 receptors, the psychotic symptoms may be ameliorated by normalising salience abnormalities in the reward system.
AB - BACKGROUND: Psychotic symptoms have been linked to salience abnormalities in the brain reward system, perhaps caused by a dysfunction of the dopamine neurotransmission in striatal regions. Blocking dopamine D2 receptors dampens psychotic symptoms and normalises reward disturbances, but a direct relationship between D2 receptor blockade, normalisation of reward processing and symptom improvement has not yet been demonstrated. The current study examined the association between blockade of D2 receptors in the caudate nucleus, alterations in reward processing and the psychopathology in a longitudinal study of antipsychotic-naïve first-episode schizophrenia patients.METHODS: Twenty-two antipsychotic-naïve first-episode schizophrenia patients (10 males, mean age 23.3) and 23 healthy controls (12 males, mean age 23.5) were examined with single-photon emission computed tomography using 123I-labelled iodobenzamide. Reward disturbances were measured with functional magnetic resonance imaging (fMRI) using a modified version of the monetary-incentive-delay task. Patients were assessed before and after 6 weeks of treatment with amisulpride.RESULTS: In line with previous results, patients had a lower fMRI response at baseline (0.2 ± 0.5 v. 0.7 ± 0.6; p = 0.008), but not at follow-up (0.5 ± 0.6 v. 0.6 ± 0.7), and a change in the fMRI signal correlated with improvement in Positive and Negative Syndrome Scale positive symptoms (ρ = -0.435, p = 0.049). In patients responding to treatment, a correlation between improvement in the fMRI signal and receptor occupancy was found (ρ = 0.588; p = 0.035).CONCLUSION: The results indicate that salience abnormalities play a role in the reward system in schizophrenia. In patients responding to a treatment-induced blockade of dopamine D2 receptors, the psychotic symptoms may be ameliorated by normalising salience abnormalities in the reward system.
KW - Antipsychotic
KW - dopamine
KW - fMRI
KW - reward
KW - schizophrenia
KW - SPECT
KW - Corpus Striatum/diagnostic imaging
KW - Dopamine D2 Receptor Antagonists/therapeutic use
KW - Humans
KW - Amisulpride/therapeutic use
KW - Tomography, Emission-Computed, Single-Photon
KW - Male
KW - Case-Control Studies
KW - Young Adult
KW - Magnetic Resonance Imaging
KW - Schizophrenia/diagnostic imaging
KW - Denmark
KW - Adult
KW - Female
KW - Reward
KW - Longitudinal Studies
U2 - 10.1017/S0033291718004099
DO - 10.1017/S0033291718004099
M3 - Journal article
C2 - 30642415
SN - 0033-2917
VL - 50
SP - 220
EP - 228
JO - Psychological Medicine
JF - Psychological Medicine
IS - 2
ER -